Market LIVE
Published markets; coverage varies by country
Product profile · United States

BLOXIVERZ

 ·  Patent Litigation & Settlement History ↓

IngredientNEOSTIGMINE METHYLSULFATE
Application typeNDA
Application204078
Product001
Dosage formSOLUTION
RouteINTRAVENOUS
Strength5MG/10ML (0.5MG/ML)
Approval date2013-05-31
Marketing statusDiscontinued
Status event—
ApplicantEXELA PHARMA
Product source

Current GenericRadar decision

Year—
SelectionEXISTING_GENERIC
ReviewCOMPLETED
Anchor type—
Anchor date—
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2015-12-28
Status event—

ANDA 207042/001 Final 2015-12-28; FDA RLD brand or first generic source. Exact RLD product and competing same-day/earlier ANDAs should be checked.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
207042 / 001FINAL_APPROVAL · FINAL_APPROVED2015-12-28—HIKMA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208405 / 001FINAL_APPROVAL · FINAL_APPROVED2017-04-26—PH HEALTH LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
209933 / 001FINAL_APPROVAL · FINAL_APPROVED2017-09-25—AMPHASTAR PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
209182 / 001FINAL_APPROVAL · FINAL_APPROVED2018-05-04—AMERICAN REGENT INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210051 / 001FINAL_APPROVAL · FINAL_APPROVED2018-06-15—AMNEAL EU LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
209135 / 001FINAL_APPROVAL · FINAL_APPROVED2018-07-10—DR REDDYS LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210989 / 001FINAL_APPROVAL · FINAL_APPROVED2018-08-22—J MOLNER HOLDINGS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212512 / 001FINAL_APPROVAL · FINAL_APPROVED2019-05-13—BE PHARMACEUTICALS AGNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212968 / 001FINAL_APPROVAL · FINAL_APPROVED2019-10-16—GLAND PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212804 / 001FINAL_APPROVAL · FINAL_APPROVED2021-04-05—MEITHEAL PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213074 / 001FINAL_APPROVAL · FINAL_APPROVED2021-04-20—CAPLIN STERILES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
210652 / 001FINAL_APPROVAL · FINAL_APPROVED2021-10-01—REGCON HOLDINGS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212627 / 001FINAL_APPROVAL · FINAL_APPROVED2022-11-03—NIVAGEN PHARMACEUTICALS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
208230 / 001FINAL_APPROVAL · FINAL_APPROVED2022-11-25—AVET LIFESCIENCES PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
216542 / 001FINAL_APPROVAL · FINAL_APPROVED2023-02-17—SAGENT PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213244 / 001FINAL_APPROVAL · FINAL_APPROVED2023-11-02—EUGIA PHARMA SPECIALITIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 16 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
207042 / 001HIKMA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2015-12-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208405 / 001PH HEALTH LTDFINAL_APPROVAL · FINAL_APPROVED2017-04-26 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
209933 / 001AMPHASTAR PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2017-09-25 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
209182 / 001AMERICAN REGENT INCFINAL_APPROVAL · FINAL_APPROVED2018-05-04 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210051 / 001AMNEAL EU LTDFINAL_APPROVAL · FINAL_APPROVED2018-06-15 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
209135 / 001DR REDDYS LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2018-07-10 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210989 / 001J MOLNER HOLDINGS INCFINAL_APPROVAL · FINAL_APPROVED2018-08-22 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212512 / 001BE PHARMACEUTICALS AGFINAL_APPROVAL · FINAL_APPROVED2019-05-13 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212968 / 001GLAND PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2019-10-16 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212804 / 001MEITHEAL PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2021-04-05 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213074 / 001CAPLIN STERILES LTDFINAL_APPROVAL · FINAL_APPROVED2021-04-20 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
210652 / 001REGCON HOLDINGS LLCFINAL_APPROVAL · FINAL_APPROVED2021-10-01 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212627 / 001NIVAGEN PHARMACEUTICALS LLCFINAL_APPROVAL · FINAL_APPROVED2022-11-03 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
208230 / 001AVET LIFESCIENCES PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2022-11-25 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
216542 / 001SAGENT PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2023-02-17 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213244 / 001EUGIA PHARMA SPECIALITIES LTDFINAL_APPROVAL · FINAL_APPROVED2023-11-02 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.